Ginkgo, Tangible Scientific, Inductive Bio Launch ADME-One™ for AI Drug Discovery

Ginkgo Bioworks, in a strategic alliance with Tangible Scientific and Inductive Bio, has launched ADME-One™, an artificial intelligence-powered platform engineered to embed critical pharmacokinetic (PK) projections earlier into the drug discovery pipeline. This initiative addresses a long-standing industry challenge by providing high-throughput ADME data and AI-driven human pharmacokinetic insights at the pivotal hit identification stage, enhancing the efficiency and success rates of small molecule development across pharmaceutical and biotechnology sectors.

Integrated Platform Redefines Early Drug Discovery

Ginkgo Bioworks, recognized for its cell programming capabilities, has joined forces with Tangible Scientific, specializing in high-throughput ADME solutions, and Inductive Bio, an AI-driven drug discovery firm, to unveil ADME-One™. This new platform is designed to overcome a persistent bottleneck in small molecule development by integrating crucial ADME (absorption, distribution, metabolism, and excretion) parameters directly into the initial hit identification phase. The collaboration leverages distinct strengths to deliver a cohesive solution that promises to streamline early-stage research.

ADME-One™ offers a comprehensive Tier 1 ADME panel, providing fundamental data on drug-like properties. Critically, it combines this with advanced AI algorithms to generate human pharmacokinetic projections, a capability traditionally reserved for later, more costly stages of development. The platform further integrates streamlined compound management, establishing an end-to-end workflow intended to accelerate lead optimization and minimize attrition rates in preclinical research across various biomedical fields.

By shifting these complex pharmacokinetic assessments earlier, ADME-One™ empowers researchers to make more informed decisions about compound viability and potential efficacy. This early insight allows for the rapid deselection of candidates with unfavorable ADME profiles, thereby saving significant resources, time, and effort that would otherwise be expended on compounds unlikely to succeed in clinical trials. The platform's U.S.-based operation ensures supply chain stability and data security for enterprise users.

Technological Convergence and Operational Efficiency

The technological backbone of ADME-One™ relies on the synergy of high-throughput experimental data generation and sophisticated artificial intelligence. Tangible Scientific contributes its expertise in scalable ADME assays, ensuring rapid and reliable data collection across a large number of compounds. This foundational data feeds into Inductive Bio's AI models, which are trained to predict human pharmacokinetic behavior with increased accuracy, moving beyond traditional in vitro and in silico approximations prevalent in current drug development.

This integration represents a significant leap from conventional, sequential drug discovery processes. Instead of waiting for lead compounds to progress through multiple stages before pharmacokinetic properties are fully assessed, ADME-One™ provides these critical insights concurrently with initial compound screening. The platform’s design for high-throughput processing translates directly into faster cycle times for lead identification and optimization, a key operational advantage for any drug developer or biotechnology startup.

Furthermore, the platform's fully U.S.-based workflow offers strategic advantages, particularly concerning regulatory compliance and intellectual property protection for enterprise buyers. This localized approach allows for tighter quality control and reduces logistical complexities often associated with globalized research pipelines. Coupled with its competitive price point, ADME-One™ positions itself as an accessible yet advanced solution for a broad spectrum of research organizations aiming to optimize their early drug discovery efforts and reduce overall R&D expenditure.

Broad Impact Across the Biomedical Ecosystem

The introduction of ADME-One™ carries substantial implications for various sectors within the life sciences. For **Pharmaceutical & Drug Development** companies and **Biotechnology Startups**, the platform promises a reduction in the time and cost associated with advancing drug candidates, by identifying and deprioritizing problematic molecules earlier. This enhanced efficiency can accelerate pipelines, potentially leading to faster market entry for novel therapies and improving return on R&D investments, a critical metric for industry analysts and investors.

**Academic Research & Universities** and **Clinical Research & CROs** stand to benefit from access to more robust and predictive early-stage pharmacokinetic data. This capability supports stronger grant applications, more effective preclinical studies, and streamlined transitions into clinical trials. For CROs, offering ADME-One™ services can enhance their competitive edge, attracting clients seeking cutting-edge, integrated solutions for compound characterization and optimization, thereby increasing their service revenue and market share.

Beyond traditional drug development, sectors such as **Agricultural & Food Science** could leverage similar ADME principles for agrochemical design, while **Diagnostic & Clinical Labs** and **Government & National Labs** gain a powerful tool for compound characterization, toxicology screening, and understanding environmental impacts of chemicals. The platform's ability to provide early, actionable insights into how compounds interact with biological systems represents a foundational advancement relevant wherever chemical-biological interactions are critical for healthcare innovation and environmental stewardship.